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Introduction
A possible relationship between the thyroid gland and
its hormones and human breast cancer has been
suggested for many years, although published data is still
confusing.
In the past it has been reported [1-3] that Japanese
women suffering from Hashimoto's thyroiditis have a five
times higher risk of developing breast cancer than women
without thyroid disorders. The authors of this report
suggested [4] that mild hypothyroidism present in
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I n t r o d u c t i o n.  The aim of the study was to compare the activity of type 1 5'iodothyronine deiodinase (5'D1) in breast cancer
tissue and in non-cancerous breast tissue taken from the opposite side to the location of the tumour.
M a t e r i a l.  The material consisted of 36 samples of breast cancer tissues (grades G1 to G3) and non-cancerous control
tissues, which were collected during radical mastectomy or local tumour resection.
M e t h o d s.  Tissues were homogenized and protein concentration was estimated acc. to the Bradford method. 5'D1 activity
was measured by quantification of the radioactive iodide released from 3'5'[ 125I]-rT3.
Re s u l t s.  The activity of 5'D1 in non-cancerous breast tissues was found to be very low or non-measurable. On the contrary,
in cancer tissues from the same breasts – especially in G1 and G2 tumours, the enzyme activity was significantly increased. Also
in small tumours (first and second grade clinical stage) 5'D1 activity was high.
C o n c l u s i o n s.  Our data may suggest that increased activity of 5-deiodinase type I can lead to elevated de novo production
of triiodothyronine in breast cancer tissues and that the thyroid hormone plays a part especially in early stage of carcinogenesis.
AktywnoÊç 5'dejodynazy typu pierwszego jest znaczàco podwy˝szona w raku sutka
W s t ´ p.  Celem pracy by∏o porównanie aktywnoÊci enzymatycznej 5' jodotyroninowej dejodynazy typu pierwszego (5'D1)
w tkance raków piersi i w niezmienionej nowotworowo tkance gruczo∏u piersiowego, wzi´tej z przeciwnego bieguna w stosun-
ku do lokalizacji guza.
M a t e r i a∏.  Materia∏ stanowi∏o 36 próbek tkanek guzów sutka (stopnie z∏oÊliwoÊci G1 do G3) oraz ta sama iloÊç tkanek
gruczo∏u piersiowego, niezmienionych nowotworowo, zebranych podczas radykalnej mastektomii lub lokalnej tumorektomii.
M e t o d y.  Uzyskane tkanki zosta∏y poddane homogenizacji w celu izolacji bia∏ka enzymatycznego. St´˝enie bia∏ka ozna-
czono metodà Bradforda. AktywnoÊç 5'D1 zosta∏a zmierzona za pomocà zliczania jodu radioaktywnego, uwolnionego
z 3'5'[125I]-rT3, który s∏u˝y∏ do przeprowadzenia reakcji enzymatycznej.
W y n i k i.  AktywnoÊç 5'D1 w nienowotworowych tkankach piersi by∏a bardzo niska lub niewykrywalna. W przeciwieƒstwie do
tego, tkanki raków pochodzàce z tych samych gruczo∏ów piersiowych wykazywa∏y podwy˝szonà aktywnoÊç 5'D1, w szczegól-
noÊci w guzach G1 i G2. Równie˝ w ma∏ych guzach, w pierwszym i drugim stopniu klasyfikacji klinicznej, obserwowano zna-
czàcy wzrost aktywnoÊci 5'D1.
Wnioski.  Nasze dane mogà sugerowaç, ˝e podwy˝szona aktywnoÊç 5-dejodynazy typu I mo˝e prowadziç do podwy˝szonej pro-
dukcji trijodotyroniny w tkance guzów piersi i ˝e hormony tarczycy mogà mogà pe∏niç jakàÊ rol´, szczególnie we wczesnej fa-
zie karcinogenezy.
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Hashimoto's patients might predispose to breast cancer.
However, in another retrospective study Goldman et al.
found that patients with Hashimoto's thyroiditis have had
the lowest percent of deaths due to breast cancer. The
possible link between development of breast cancer and
hypothyroidism was also neglected.
In a prospective, 18-year long study of 10.000 women
residing on Guernsey, all those who developed breast
cancer had a negative history of thyroid pathologies and
presented no abnormalities of the serum level of
triiodothyronine (T3), thyroxine (T4) and pituitary TSH
in the decade before their malignancy was diagnosed [4]).
Most recently, due to the molecular findings the
possible relationship between breast carcinogenesis and
thyroid hormones was again brought to attention
[Puzianowska et al. 2001 – 5]. Firstly, high expression of
Na/I symporter (the membrane iodide transporter present
in thyroid cell membranes) was discovered both in healthy
and cancerous breast tissues [6-8]. The possibility that
the expression of thyroid hormone and function of its
nuclear receptors [TRs] in cancer tissues can be disturbed
was supported by studies on liver cancer [Lin KH et al. –
9], renal clear cell cancer [Puzianowska et al. – 10, Kamiya
et al. – 11], thyroid cancers [Puzianowska et al. – 12] and
other tumours. The possibilities that triiodothyronine
receptor function is changed in breast cancer was also
cofirmed by Ali et al. [13] and Futreal et al. [14], who
discovered the loss of heterozygosity on chromosome 3
and on chromosome 17 i.e. in regions of chomosomes
where genes for TRβ and TRα are present.
In addition it is well known that biologically active
thyroid hormone – T3, is a product of local thyroxine
monodeiodination – the reaction which is catalyzed by
5'-deiodinase type I, the enzyme present in almost all
human cells [15, 16]. Enzymatic activity and its gene
expression have been examined in some cancers and
a significant decrease of gene expression and enzyme
activity was found in renal clear cell cancer and thyroid
cancer [Pachucki et al. 17 Ambrodziak et al. 17]. As there
exists no data on local triiodothyronine formation in
human breast tissues we decided to investigate the 5'-
deiodinase type I activity both in human non-cancerous
breast tissue and in breast cancer of different grades of
differentiation.
Material
Tissues were obtained from patients with breast cancer, who
underwent surgery as the first step of oncological treatment.
Samples from post-chemotherapy patients were not included.
The patients had no history of thyroid disease in the past,
therefore we could be certain that breast cancer cell metabolism
was not disturbed by cytostatic drugs or thyroid disorders.
During radical mastectomy or tumour resection 36 tissue
samples were obtained. All patients had samples taken from
the tumour, as well as from the side opposite to the tumour – i.e.
macroscopically normal tissue. These non-cancerous tissues
were treated as controls. Immediately after surgery the samples
were frozen in liquid nitrogen and kept at -70° C until needed.
Morphologically different types of cancers were present
including intraductal, lobular, tubulo-lobular, tubular, medular,
mucinous and apocrine carcinoma.
According to the histopathological classification three
differentiation grades were represented in the study group (G1
– 14 samples, G2 – 13 samples and G3 – 9 samples). According
to TNM classification there were 13 stage 1, 21 stage 2 and 2
stage 3 tumours.
At hospital admission each patient had blood sample taken
in order to measure the levels of thyroid hormones. After the
clot was formed, the blood sample was centrifuged. Obtained
plasma was collected and stored at -70° C until needed. All
patients were clinically euthyroid and remained in good health
prior to the operation. There was no postoperative mortality.
The study was approved by the Ethical Committee of the
Medical University of Warsaw (KB/210/2001).
Methods
S a m p l e  p r e p a r a t i o n
Tissue samples were defrozen and then homogenized in ice
bath. Homogenization was performed in ice-old homogenisation
buffer (0.02 M TRIS-HCl, 1mmEDTA, 10mMDTT-
dithiothreitol and 0.25 M glucose, pH 7.0). Protein concentration
was estimated by Bradford's method, using bovine albumin as
a standard.
D e i o d i n a s e  a s s a y
5'D1 activity was measured by quantification of the radioactive
iodide released from 3'5'[125I]-rT3. Before each assay, water
diluted 3'5'[125I]-rT3 was purified by Sephadex LH 20 mini-
column chromatography by successive washing with 20 ml of
H2O followed by elution with 2 ml of 75% ethanol in 0.5 ml
fractions. From the fraction with the highest activity (30 000
CPM to 40 000 CPM per 60 µl), 60 µl were added to each
reaction tube. This amount of 75% alcohol did not affect the
reaction. Incubations were done at 37° C in 0.1 M phosphate
buffer, pH=7.0 (0.1 M KPO4 and 1 mM EDTA) with 1 µM
unlabeled rT3 and 20 mM DTT. Incubation time was 45 minutes.
Reactions were stopped by placing the samples in the ice bath.
Iodothyronines were then precipitated by adding 2 volumes of
horse serum and 1 volume of 50% TCA. Samples were vortexed
for 1.5 minutes and centrifuged (15 000G, 10 minutes). An
aliquot of the supernatant containing [125I] (not iodothyronines)
was counted in a gamma counter (Wizard-1470, Wallac). Each
assay was performed twice. At least one internal control was
measured in all assays (human liver tissue with high activity
level).
f T 3 , f T 4 ,  T S H  a s s a y s
To measure plasma thyroid hormone concentration we used
fT3, fT4, TSH electrochemiluminescence immunoassays
"ECLIA" (Roche). All sera were measured in one series and in
identical conditions.
S t a t i s t i c a l  a n a l y s i s
Statistical analysis was performed with STATISTICA software.
All data is reported as median and minimal and maximal value
are given. Groups were compared with the Mann-Whitney non-
parametrical test for independent trials.
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Results
5'D1 activity in normal, non-cancerous breast tissue
was low in 32 samples – 89% and below detectable values
in 4 samples – 11%. Non-cancerous tissues with
measurable levels of enzyme activity were treated as
controls. Contrary to the non-cancerous tissues we found
high 5'D1 activity in 80.% tumours, which according to
histopathological grading included: 79% of G1 tumours,
100% of G2 tumours and 56% of G3 tumours. 5'D1
activity in group G1 was 22 times higher than in controls.
The difference was statistically significant (p=0.003).
5'D1 activity in group G2 was 3 times higher than in
controls, and the result was also statistically significant
(p=0.0003). We also observed slightly increased activities
of the enzymes in group G3 but it was not statistically
significant (Figure 1). The median value for G1 was
12.75 fmol/mg*min compared with 0.57 fmol/mg*min in
non-cancerous tissues. The median value for G2 was
2.36 fmol/mg*min compared with 0.72 fmol/mg*min in
non-cancerous tissues. The median value for G3 was
0.7 fmol/mg*min compared with 0.59 fmol/mg*min in
non-cancerous tissues.
We found that in 85% of small tumours (up to 2 cm
in diameter) median 5'D1 activity was 10 times higher
than in control tissues. The difference is statistically
significant (p=0.004). In 76% of medium-sized tumours
(2 cm to 5cm in diameter) 5'D1 activity was 4 times higher
than in control tissues. The difference is statistically
significant (p=0.002) (Figure 2). There were only 2 large
tumours (over 5 cm in diameter) and they were discarded
from further analysis. The median value for small tumours
was 5.53 fmol/mg*min compared with 0.57 fmol/mg*min
in control tissues. The median value for medium-sized
tumours was 2.99 fmol/mg*min compared with
0.71 fmol/mg*min in control tissues.
To check if these findings implicate changes in blood
thyroid hormones levels we performed fT3, fT4, TSH
immunoassays. FT3 levels were normal in all patients
(Figure 3). Only one patient had a little lower FT4 level
(Figure 4). In 4 cases TSH was elevated and in two
decreased in comparison with normal range (Figure 5).
Discussion and conclusions
5'D1 is present in many different organs and the highest
5'D1 activity was found in the thyroid, kidneys and liver
[15-18]. There is no data available on 5'D1 activity in
human healthy breast tissue. There is only one report
proving the presence of 5'D1 in rat breast tissue [19]. The
results of our study identifying the activity of 5'D1 in
Figure 1. 5'D1 activity according to histopathological grading
Figure 2. 5'D1 activity according to clinical classification
Figure 3. FT3 levels (reference values 1,8 – 4,62)
Figure 4. FT4 levels (reference values 0,93 – 1,7)
Figure 5. TSH levels (reference values 0,27-4,2)
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human breast tissue are the first published in literature.
We have found that in non-cancerous tissue the activity of
the enzyme is very low and in some cases below the limit
of detection. Values remained low even though different
protein concentration, incubation time, reagents
concentrations were used. Decreased 5'D1 activity was
described in thyroid cancer, renal clear cell carcinoma
[17, 20] and primary liver cancer [unpublished own data]
but in healthy tissues of these organs 5'D1 activity remains
relatively high [20]. On the contrary, we report increased
5'D1 activity in breast cancer. It is of interest that
significantly elevated values have been found in highly
differentiated tumours of G1 and G2.
The 5'D1 expression is strongly stimulated by thyroid
hormone and the promotor of human 5'D1 gene has two
thyroid hormone responsive elements – TRE [21, 22].
Overexpression of hdio gene may be a simple explanation
of increased 5'D1 activity, but it needs further studies on
mRNA level. We may suspect high promotor activity via
TREs or some mutations which may activate the
promotor of hdio gene. Moreover, mutated TR (thyroid
receptors) in breast cancer may activate TREs. Many
other factors such as cytokines, glucocorticoids, retinoids,
cAMP are known to regulate, directly or indirectly, 5'D1
activity in various rat organs [16, 18, 19, 23] and probably
in humans. They possibly play role in stimulating or
inhibiting human deiodinase. We do not have an
immediate explanation for our findings show a higher
activity of the enzyme than those reported in other tissues.
High 5'D1 activity in most breast cancers may be one of
the signals that intracellular metabolism is changed by
neoplasmatic process.
In many neoplasmatic conditions changed values of
fT3, fT4 and TSH are described and referred to as the
"sick euthyroid syndrome" [24]. As abnormal thyroid
hormones levels were also reported in patients with breast
cancer but published data were controversial [3, 24, 25]
we decided to measure thyroid hormones levels in the
entire group of patients from whom samples had been
obtained.
All our patients remained hormonally euthyroid. We
conclude that monodeiodination of tertaiodothyronine
by increased 5'D1 activity in breast cancer tissue is not
sufficient to influence systemic fT3, fT4 and TSH levels.
In conclusion, the present study shows high
enzymatic activity of 5'D1 in human breast cancer tissue
but further research on mRNA level is necessary to assess
the expression of the hdio gene.
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